Rationale and design of the Helping Ease Renal failure with Bupi Yishen compared with the Angiotensin II Antagonist Losartan (HERBAAL) trial: a randomized controlled trial in non-diabetes stage 4 chronic kidney disease-Reference-Cited by-同舟云学术

Rationale and design of the Helping Ease Renal failure with Bupi Yishen compared with the Angiotensin II Antagonist Losartan (HERBAAL) trial: a randomized controlled trial in non-diabetes stage 4 chronic kidney disease

Published:2015-09-08 Issue:1 Volume:15 Page:
ISSN:1472-6882
Container-title:BMC Complementary and Alternative Medicine
language:en
Short-container-title:BMC Complement Altern Med

Author:

Mao Wei,Zhang Lei,Zou Chuan,Li Chuang,Wu Yifan,Su Guobin,Guo Xinfeng,Wu Yuchi,Lu Fuhua,Lin Qizhan,Wang Lixin,Bao Kun,Xu Peng,Zhao Daixin,Peng Yu,Liang Hui,Lu Zhaoyu,Gao Yanxiang,Jie Xina,Zhang La,Wen Zehuai,Liu Xusheng

Publisher

Springer Science and Business Media LLC

Subject

Complementary and alternative medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12906-015-0830-1.pdf

Reference38 articles.

1. W C, H W, XQ D. Epidemiologic study of chronic kidney disease in Guangzhou urban area. Chin J Nephrol. 2007;17(298):2038–47.

2. Zhang L, Zuo L, Xu G, Wang F, Wang M, Wang S, et al. Community-based screening for chronic kidney disease among populations older than 40 years in Beijing. Nephrol Dial Transplant. 2007;22(4):1093–9.

3. Astor BC, Hallan SI, Miller ER, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. 2008;167(10):1226–34.

4. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–47.

5. Abboud H, Henrich WL. Clinical practice. Stage IV chronic kidney disease. N Engl J Med. 2010;362(1):56–65.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of Sanqi Qushi Granule in patients with idiopathic membranous nephropathy ——protocol of a multicenter, randomized control trial (SQ-AUTUMN);BMC Complementary Medicine and Therapies;2023-04-27

2. Bupi Yishen formula attenuates kidney injury in 5/6 nephrectomized rats via the tryptophan-kynurenic acid-aryl hydrocarbon receptor pathway;BMC Complementary Medicine and Therapies;2021-08-10

3. Bupi Yishen Formula Versus Losartan for Non-Diabetic Stage 4 Chronic Kidney Disease: A Randomized Controlled Trial;Frontiers in Pharmacology;2021-01-29

4. Anticancer Properties of Lobetyolin, an Essential Component of Radix Codonopsis (Dangshen);Natural Products and Bioprospecting;2020-11-07

5. Chemical Analysis and Multi-Component Determination in Chinese Medicine Preparation Bupi Yishen Formula Using Ultra-High Performance Liquid Chromatography With Linear Ion Trap-Orbitrap Mass Spectrometry and Triple-Quadrupole Tandem Mass Spectrometry;Frontiers in Pharmacology;2018-06-08